Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Drug-Related Side Effects and Adverse Reactions 10Head and Neck Neoplasms 9Radiation Injuries 7Lung Neoplasms 7Ovarian Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Squamous Cell Carcinoma of Head and Neck 5Carcinoma, Ovarian Epithelial 5Sarcoma 3Prostatic Neoplasms 3Neurotoxicity Syndromes 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia 3Hodgkin Disease 3Breast Neoplasms 3Xerostomia 2Waldenstrom Macroglobulinemia 2Urinary Bladder Neoplasms 2Testicular Neoplasms 2Small Cell Lung Carcinoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neutropenia 2Neuroectodermal Tumors, Primitive, Peripheral 2Mucositis 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2

Interventions

avasopasem manganese 1Surgical Procedures, Operative 1Radiation 1Induction Chemotherapy 1Heart Rate 1Drug Therapy 1Amifostine 1Alginates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Esophagitis × Amifostine × Clear all
NCT00081315 2007-08-21

Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer

MedImmune LLC

Phase 2 Completed
130 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Esophagitis, Pneumonia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡